These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20410329)

  • 1. Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.
    Held DM; Shurtleff AC; Fields S; Green C; Fong J; Jones RG; Sesardic D; Buelow R; Burke RL
    Clin Vaccine Immunol; 2010 Jun; 17(6):930-6. PubMed ID: 20410329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An improved method for development of toxoid vaccines and antitoxins.
    Jones RG; Liu Y; Rigsby P; Sesardic D
    J Immunol Methods; 2008 Aug; 337(1):42-8. PubMed ID: 18571196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of new formalin-detoxified botulinum neurotoxin toxoids.
    Keller JE
    Clin Vaccine Immunol; 2008 Sep; 15(9):1374-9. PubMed ID: 18667637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B).
    Shearer JD; Vassar ML; Swiderski W; Metcalfe K; Niemuth N; Henderson I
    Vaccine; 2010 Oct; 28(45):7313-8. PubMed ID: 20816903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.
    Ben David A; Diamant E; Barnea A; Rosen O; Torgeman A; Zichel R
    Clin Vaccine Immunol; 2013 Aug; 20(8):1266-73. PubMed ID: 23761665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing toxin-based vaccines against botulism.
    Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
    Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal immunisation with Clostridium botulinum type C 16 S toxoid and its non-toxic component.
    Mahmut N; Inoue K; Fujinaga Y; Arimitsu H; Sakaguchi Y; Hughes L; Hirst R; Murphy T; Tsuji T; Watanabe T; Ohyama T; Karasawa T; Nakamura S; Yokota K; Oguma K
    J Med Microbiol; 2002 Oct; 51(10):813-820. PubMed ID: 12435059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics study of immunological response to Clostridium botulinum toxin.
    Dezfulian M; Bitar RA; Bartlett JG
    J Clin Microbiol; 1987 Jul; 25(7):1336-7. PubMed ID: 3301895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative vaccination against equine botulism (BoNT/C).
    Frey J; Eberle S; Stahl C; Mazuet C; Popoff M; Schatzmann E; Gerber V; Dungu B; Straub R
    Equine Vet J; 2007 Nov; 39(6):516-20. PubMed ID: 18065309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition.
    Aoki KR; Smith LA; Atassi MZ
    Crit Rev Immunol; 2010; 30(2):167-87. PubMed ID: 20370628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.
    Baldwin MR; Tepp WH; Pier CL; Bradshaw M; Ho M; Wilson BA; Fritz RB; Johnson EA; Barbieri JT
    Infect Immun; 2005 Oct; 73(10):6998-7005. PubMed ID: 16177380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B.
    Shi DY; Chen BY; Mao YY; Zhou G; Lu JS; Yu YZ; Zhou XW; Sun ZW
    Hum Vaccin Immunother; 2019; 15(3):755-760. PubMed ID: 30433836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.
    Yu Y; Shi D; Liu S; Gong ZW; Wang S; Sun Z
    Hum Vaccin Immunother; 2015; 11(2):468-73. PubMed ID: 25483668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid.
    Siegel LS
    J Clin Microbiol; 1989 Aug; 27(8):1906-8. PubMed ID: 2768475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Egg yolk antibodies for detection and neutralization of Clostridium botulinum type A neurotoxin.
    Trott DL; Yang M; Gonzalez J; Larson AE; Tepp WH; Johnson EA; Cook ME
    J Food Prot; 2009 May; 72(5):1005-11. PubMed ID: 19517727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
    Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
    Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression, purification and development of neutralizing antibodies from synthetic BoNT/B LC and its application in detection of botulinum toxin serotype B.
    Ponmariappan S; Jain S; Sijoria R; Tomar A; Kumar O
    Protein Pept Lett; 2012 Mar; 19(3):288-98. PubMed ID: 21933129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles.
    Ruwona TB; Xu H; Li J; Diaz-Arévalo D; Kumar A; Zeng M; Cui Z
    Hum Vaccin Immunother; 2016 May; 12(5):1188-92. PubMed ID: 26837242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.
    Khouri JM; Motter RN; Arnon SS
    Vaccine; 2018 Apr; 36(15):2041-2048. PubMed ID: 29475762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor.
    Sharma R; Zhao H; Al-Saleem FH; Ubaid AS; Puligedda RD; Segan AT; Lindorfer MA; Bermudez R; Elias M; Adekar SP; Simpson LL; Taylor RP; Dessain SK
    Mol Immunol; 2014 Feb; 57(2):247-54. PubMed ID: 24184879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.